Director, Integrated Product Medical Lead

 

At Bayer we’re visionaries, driven to solve the world’s toughest challenges and striving for a world where 'Health for all Hunger for none’ is no longer a dream, but a real possibility. We’re doing it with energy, curiosity and sheer dedication, always learning from unique perspectives of those around us, expanding our thinking, growing our capabilities and redefining ‘impossible’. There are so many reasons to join us. If you’re hungry to build a varied and meaningful career in a community of brilliant and diverse minds to make a real difference, there’s only one choice.

 

Director, Integrated Product Medical Lead 

 

 

The Integrated Product Medical Lead (IPML) is a key figure for advancing the oncology early development portfolio. You will create significant impact through the successful progression of global development programs and the expansion of our pipeline.

 

The IPML sets the vision and strategic direction of assigned programs and is responsible for a medically and clinically sound end-to-end development strategy for our products across various modalities, biologies and indications, representing the full value chain from pre-D1 up to hand-over to late-stage drug development (following Proof-of-Concept and the decision to enter pivotal studies).

 

The IPML builds an end-to-end clinical strategy and is responsible for the successful execution of development programs on behalf of Early Clinical Development Oncology, providing clinical-scientific leadership for one or more global development programs with full decision-making authority in his/her sphere of influence.

 

Together with cross-functional IPT members, the IPML drives the creation and maintenance of a target product and target value profile to maximize the clinical success of development programs and therefore significantly shapes the value of the product.  Already during the pre-clinical stages within development, the IPML is responsible for driving value and differentiation of ONC assets based on the scientific hypothesis of a molecule as well as the current and future standard of care in the relevant therapeutic area.

 

Furthermore, the IPML co-leads the successful incorporation of novel assets into the pipeline through supporting internal (e.g., target identification) and external innovation (e.g., due diligences) efforts. In addition, every IPML is accountable for significantly shaping functional excellence within Early Clinical Development Oncology by driving core project, people, and innovative clinical development topics under a peer-reviewed setting, as well as pushing the boundaries of drug development in close collaboration with internal and external researchers.

 

YOUR TASKS AND RESPONSBILITIES

 

The primary responsibilities of the Integrated Product Medical Lead are to:

 

• Acts as the clinical leader and primary clinical representative for the global program(s) assigned to him/her and represents them both, internally and externally facing. As such, the IPML ensures consistent high quality and speed of functional deliverables to drive sustained value creation for patients and the business and ensures an “end-to-end” clinical vision and strategy for the respective asset is defined. The IPML pushes the boundaries of early drug development to accelerate and improve decision making, while continuously implementing the patient’s perspective and always ensuring patient’s safety and benefit;
• In preparation for assets entering the portfolio, the IPML develops a clinical vision if and how a molecule can address an unmet medical need considering the molecule’s scientific hypothesis and the current and future treatment landscape. Based on this vision, the IPML designs a clinical strategy to guide preclinical and clinical development enabling early and definitive decision-making. In line with the strategy, the IPML plans and executes clinical trials focusing on patient centricity, urgency and speed ensuring patients benefit at any point in time during trial conduct and enabling the collection of all relevant information for further seamless clinical development. The IPML is responsible for study medical/safety aspects and risk-benefit assessments supported by Pharmacovigilance and Clinical Science;
• Is accountable for the timely delivery of milestones, mitigates roadblocks and is empowered to take decisions to effectively execute on the clinical strategy;
• Supports the preclinical evaluation and validation of new oncology assets in line with the overarching RED ONC strategy focusing on value, differentiation, and unmet medical need (e.g., through interacting with BD&L, LEAPS, Collaboration to Cure Hubs, CoLab incubator);
• In alignment with the overall ECDO and RED-ONC strategy, identifies new opportunities for collaboration and manages excellent re